A research team at Memorial Sloan Kettering Cancer Center (MSK) has made new insights into how the body forms immune cell ...

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

Immunotherapy is a modern approach to cancer treatment that uses a patient's own immune system to help fight tumors.

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

Anixa Biosciences CEO Amit Kumar discusses the biotech’s plans for advancing a breast cancer vaccine in 2025. The cancer ...

Prostate cancer presents challenges in detection, treatment, and management. Learn about genetic risks, treatment resistance, ...

A new type of cell-based immunotherapy shows promise for B-cell lymphomas and - due to innovations in manufacturing - could make future cellular immunotherapies less expensive and more accessible to ...

The therapy, dubbed OST-HER2, uses a HER2-bioengineered form of the bacteria Listeria monocytogenes to trigger an immune ...